Skip to main content
Journal cover image

Controlled release of biologics for the treatment of type 2 diabetes.

Publication ,  Journal Article
Gilroy, CA; Luginbuhl, KM; Chilkoti, A
Published in: Journal of controlled release : official journal of the Controlled Release Society
October 2016

Type 2 diabetes is a rapidly growing disease that poses a significant burden to the United States healthcare system. Despite the many available treatments for the disease, close to half of diagnosed type 2 diabetes cases are not properly managed, largely due to inadequate patient adherence to prescribed treatment regimens. Methods for improving delivery - and thereby easing administration - of type 2 drugs have the potential to greatly improve patient health. This review focuses on two peptide drugs - insulin and glucagon-like peptide 1 (GLP-1) - for treatment of type 2 diabetes. Peptide drugs offer the benefits of high potency and specificity but pose a significant delivery challenge due to their inherent instability and short half-life. The development of insulin and GLP-1 analogs highlights the broad spectrum of drug delivery strategies that have been used to solve these problems. Numerous structural modifications and formulations have been introduced to optimize absorption, residence time, stability, route of delivery and frequency of administration. Continual improvements in delivery methods for insulin and GLP-1 receptor agonists are paving the way towards better patient compliance and improved disease management, and thereby enhanced patient quality of life.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Journal of controlled release : official journal of the Controlled Release Society

DOI

EISSN

1873-4995

ISSN

0168-3659

Publication Date

October 2016

Volume

240

Start / End Page

151 / 164

Related Subject Headings

  • Treatment Outcome
  • Pharmacology & Pharmacy
  • Insulin
  • Hypoglycemic Agents
  • Humans
  • Drug Delivery Systems
  • Diabetes Mellitus, Type 2
  • Delayed-Action Preparations
  • Blood Glucose
  • Biological Products
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gilroy, C. A., Luginbuhl, K. M., & Chilkoti, A. (2016). Controlled release of biologics for the treatment of type 2 diabetes. Journal of Controlled Release : Official Journal of the Controlled Release Society, 240, 151–164. https://doi.org/10.1016/j.jconrel.2015.12.002
Gilroy, Caslin A., Kelli M. Luginbuhl, and Ashutosh Chilkoti. “Controlled release of biologics for the treatment of type 2 diabetes.Journal of Controlled Release : Official Journal of the Controlled Release Society 240 (October 2016): 151–64. https://doi.org/10.1016/j.jconrel.2015.12.002.
Gilroy CA, Luginbuhl KM, Chilkoti A. Controlled release of biologics for the treatment of type 2 diabetes. Journal of controlled release : official journal of the Controlled Release Society. 2016 Oct;240:151–64.
Gilroy, Caslin A., et al. “Controlled release of biologics for the treatment of type 2 diabetes.Journal of Controlled Release : Official Journal of the Controlled Release Society, vol. 240, Oct. 2016, pp. 151–64. Epmc, doi:10.1016/j.jconrel.2015.12.002.
Gilroy CA, Luginbuhl KM, Chilkoti A. Controlled release of biologics for the treatment of type 2 diabetes. Journal of controlled release : official journal of the Controlled Release Society. 2016 Oct;240:151–164.
Journal cover image

Published In

Journal of controlled release : official journal of the Controlled Release Society

DOI

EISSN

1873-4995

ISSN

0168-3659

Publication Date

October 2016

Volume

240

Start / End Page

151 / 164

Related Subject Headings

  • Treatment Outcome
  • Pharmacology & Pharmacy
  • Insulin
  • Hypoglycemic Agents
  • Humans
  • Drug Delivery Systems
  • Diabetes Mellitus, Type 2
  • Delayed-Action Preparations
  • Blood Glucose
  • Biological Products